Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies
June 25, 2020

LAUSANNE, Switzerland and PALO ALTO, USA, June 25, 2020 / B3C newswire / -- Polares Medical SA, a clinical stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR), announced today the closing of a $40 million financing led by Longitude Capital (Menlo Park) with the participation of Decheng Capital (Menlo Park), Endeavour Vision (Geneva), IDO Investments (Muscat), Earlybird Venture Capital (Berlin), and Wellington Partners (Munich).

Polares Medical’s solution to MR takes a novel approach to the original concept of hemi-replacement of the mitral valve by replacing the posterior leaflet with a prosthetic leaflet designed to enhance coaptation with the native anterior leaflet. Early clinical results have demonstrated the feasibility of this concept. “Polares’ approach to treating MR has the potential to be a new first-line treatment for a large range of both functional and degenerative mitral regurgitation patients. We are excited to partner with the Polares team and this strong group of syndicate partners in the advancement of this innovative hemi-replacement technology,” said Maxwell Bikoff of Longitude Capital.

Polares Medical closed a $25 million Series A financing in 2018 to bring the former Middle Peak Medical technology from an in-vivo proof of concept to a clinical first-in-human. “We achieved the Series A financing objective of bringing the Polares technology to the clinic. With this Series B financing, we intend to advance our clinical studies in Europe and the United States,” said Jacques Essinger, Ph.D, Chairman and CEO.

About Polares Medical

Polares Medical SA is a clinical-stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR). Polares Medical was spun off in 2017 from Symetis SA prior to the acquisition of Symetis by Boston Scientific.

 

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 广西快乐10分官网安卓版下载 关于彩票停售情况 最新mg欧美厅 澳洲幸运5官方 北单比分投注 博易大师长江期货软件 排三排五中奖金额规则 重庆幸运农场计划安卓 彩票黑龙江快乐十分麻将开奖结果 王者捕鱼游戏下载 百人牛牛有挂吗 彩经网北京11选5 彩票又可以网购了 广西快乐十分开怎么玩 新加坡赌场管理专业 昨日河北20选5开奖号